Work

What is the dose of IV aspirin in acute coronary syndrome, and what literature supports this? What is the bioavailability of enteral and PR aspirin?

Year: 2026

Type: article

Abstract: No direct evidence for the bioavailability of enteral or PR aspirin in acute coronary syndrome patients was identified. For IV aspirin dosing, 250 mg and 500 mg have been used effectively to inhibit platelet function in such settings.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.23686907

Author: Tripdatabase

Language: English

Topic: Antiplatelet Therapy and Cardiovascular Diseases

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7223800154

FWCI:

Cites:

Cited by:

Related to: 10